Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans.

Reinersman JM, Johnson ML, Riely GJ, Chitale DA, Nicastri AD, Soff GA, Schwartz AG, Sima CS, Ayalew G, Lau C, Zakowski MF, Rusch VW, Ladanyi M, Kris MG.

J Thorac Oncol. 2011 Jan;6(1):28-31. doi: 10.1097/JTO.0b013e3181fb4fe2.

2.

Frequency and type of epidermal growth factor receptor mutations in African Americans with non-small cell lung cancer.

Cote ML, Haddad R, Edwards DJ, Atikukke G, Gadgeel S, Soubani AO, Lonardo F, Bepler G, Schwartz AG, Ethier SP.

J Thorac Oncol. 2011 Mar;6(3):627-30. doi: 10.1097/JTO.0b013e31820a0ec0.

3.

Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer.

Leidner RS, Fu P, Clifford B, Hamdan A, Jin C, Eisenberg R, Boggon TJ, Skokan M, Franklin WA, Cappuzzo F, Hirsch FR, Varella-Garcia M, Halmos B.

J Clin Oncol. 2009 Nov 20;27(33):5620-6. doi: 10.1200/JCO.2009.23.1431. Epub 2009 Sep 28.

4.

Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).

Lim EH, Zhang SL, Li JL, Yap WS, Howe TC, Tan BP, Lee YS, Wong D, Khoo KL, Seto KY, Tan L, Agasthian T, Koong HN, Tam J, Tan C, Caleb M, Chang A, Ng A, Tan P.

J Thorac Oncol. 2009 Jan;4(1):12-21. doi: 10.1097/JTO.0b013e3181913e28.

5.
6.
7.

Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.

Ludovini V, Bianconi F, Pistola L, Chiari R, Minotti V, Colella R, Giuffrida D, Tofanetti FR, Siggillino A, Flacco A, Baldelli E, Iacono D, Mameli MG, Cavaliere A, Crinò L.

J Thorac Oncol. 2011 Apr;6(4):707-15. doi: 10.1097/JTO.0b013e31820a3a6b.

8.

Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice.

Yamaguchi N, Vanderlaan PA, Folch E, Boucher DH, Canepa HM, Kent MS, Gangadharan SP, Majid A, Kocher ON, Goldstein MA, Huberman MS, Costa DB.

Lung Cancer. 2013 Oct;82(1):31-7. doi: 10.1016/j.lungcan.2013.07.013. Epub 2013 Aug 7.

9.

EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases.

Han HS, Eom DW, Kim JH, Kim KH, Shin HM, An JY, Lee KM, Choe KH, Lee KH, Kim ST, Koo JH, Lee HC, Lee OJ.

Clin Lung Cancer. 2011 Nov;12(6):380-6. doi: 10.1016/j.cllc.2011.02.006. Epub 2011 May 20.

PMID:
21729655
10.

Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).

Cadranel J, Mauguen A, Faller M, Zalcman G, Buisine MP, Westeel V, Longchampt E, Wislez M, Coudert B, Daniel C, Chetaille B, Michiels S, Blons H, Solassol J, De Fraipont F, Foucher P, Urban T, Lacroix L, Poulot V, Quoix E, Antoine M, Danton G, Morin F, Chouaid C, Pignon JP.

J Thorac Oncol. 2012 Oct;7(10):1490-502.

11.

EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma.

Smits AJ, Kummer JA, Hinrichs JW, Herder GJ, Scheidel-Jacobse KC, Jiwa NM, Ruijter TE, Nooijen PT, Looijen-Salamon MG, Ligtenberg MJ, Thunnissen FB, Heideman DA, de Weger RA, Vink A.

Cell Oncol (Dordr). 2012 Jun;35(3):189-96. doi: 10.1007/s13402-012-0078-4. Epub 2012 Apr 12.

12.

Genotyping non-small cell lung cancer (NSCLC) in Latin America.

Arrieta O, Cardona AF, Federico Bramuglia G, Gallo A, Campos-Parra AD, Serrano S, Castro M, Avilés A, Amorin E, Kirchuk R, Cuello M, Borbolla J, Riemersma O, Becerra H, Rosell R; CLICaP.

J Thorac Oncol. 2011 Nov;6(11):1955-9. doi: 10.1097/JTO.0b013e31822f655f.

13.

Cytomorphologic features of advanced lung adenocarcinomas tested for EGFR and KRAS mutations: a retrospective review of 50 cases.

Marotti JD, Schwab MC, McNulty NJ, Rigas JR, DeLong PA, Memoli VA, Tsongalis GJ, Padmanabhan V.

Diagn Cytopathol. 2013 Jan;41(1):15-21. doi: 10.1002/dc.21749. Epub 2011 Jun 16.

PMID:
21681971
14.

Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.

Cai G, Wong R, Chhieng D, Levy GH, Gettinger SN, Herbst RS, Puchalski JT, Homer RJ, Hui P.

Cancer Cytopathol. 2013 Sep;121(9):500-7. doi: 10.1002/cncy.21288. Epub 2013 Mar 12.

15.

Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.

D'Angelo SP, Janjigian YY, Ahye N, Riely GJ, Chaft JE, Sima CS, Shen R, Zheng J, Dycoco J, Kris MG, Zakowski MF, Ladanyi M, Rusch V, Azzoli CG.

J Thorac Oncol. 2012 Dec;7(12):1815-22. doi: 10.1097/JTO.0b013e31826bb7b2.

16.

Epidermal growth factor receptor and KRAS mutations in lung adenocarcinoma: a retrospective study of the Lebanese population.

Fakhruddin N, Mahfouz R, Farhat F, Tfayli A, Abdelkhalik R, Jabbour M, Yehia L, Mahfoud Z, Zaatari G.

Oncol Rep. 2014 Nov;32(5):2223-9. doi: 10.3892/or.2014.3406. Epub 2014 Aug 14.

PMID:
25120214
17.

Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma.

Kosaka T, Yatabe Y, Onozato R, Kuwano H, Mitsudomi T.

J Thorac Oncol. 2009 Jan;4(1):22-9. doi: 10.1097/JTO.0b013e3181914111.

18.

EGFR and KRAS mutations in Turkish non-small cell lung cancer patients: a pilot study.

Bircan S, Baloglu H, Kucukodaci Z, Bircan A.

Med Oncol. 2014 Aug;31(8):87. doi: 10.1007/s12032-014-0087-4. Epub 2014 Jun 29.

PMID:
24973952
19.

Spectrum of somatic EGFR, KRAS, BRAF, PTEN mutations and TTF-1 expression in Brazilian lung cancer patients.

Carneiro JG, Couto PG, Bastos-Rodrigues L, Bicalho MA, Vidigal PV, Vilhena A, Amaral NF, Bale AE, Friedman E, De Marco L.

Genet Res (Camb). 2014;96:e002. doi: 10.1017/S0016672314000032. Epub 2014 Mar 5.

PMID:
24594201
20.

Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients.

Bacchi CE, Ciol H, Queiroga EM, Benine LC, Silva LH, Ojopi EB.

Clinics (Sao Paulo). 2012;67(5):419-24.

Items per page

Supplemental Content

Write to the Help Desk